Eli Lilly to begin testing of baricitinib in COVID-19 patients

Trial is testing if anti-inflammatory (AA) response in rheumatoid arthritis patients on baricitinib will benefit COVID-19 patients as there is anecdotal evidence of benefit with AA drugs like tocilizumab in patients who have severe immune response due to COVID-19.


Biospace Inc.